Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 1507.

https://doi.org/10.1182/blood.V120.21.1507.1507

Published: 2012

Journal Articles

Detection of Phosphorylated and Total Flt3 and STAT5 in Whole Blood: Modulation by AC220 From Phase I and II Trials in AML

Ronald R Nepomuceno, Ph.D., Ruwanthi Gunawardane, Ph.D, Allison M Rooks, Robert C Armstrong, Ph.D.

Blood (2011) 118 (21): 2607.

https://doi.org/10.1182/blood.V118.21.2607.2607

Published: 2011

Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

Barbara A. Belli, Ph.D., Alan Dao, Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2011) 118 (21): 1538.

https://doi.org/10.1182/blood.V118.21.1538.1538

Published: 2011

Journal Articles

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

Barbara A. Belli, Ph.D., Alan Dao, B.S., Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2009) 114 (22): 2052.

https://doi.org/10.1182/blood.V114.22.2052.2052

Published: 2009

Journal Articles

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

Daniel Brigham, B.S., Barbara A. Belli, Ph.D., Michael Breider, Ph.D, DVM, Shripad Bhagwat, Ph.D., Wendell Wierenga, PhD, Robert C Armstrong, Ph.D.

Blood (2009) 114 (22): 2053.

https://doi.org/10.1182/blood.V114.22.2053.2053

Published: 2009

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat

Blood (2009) 114 (14): 2984–2992.

https://doi.org/10.1182/blood-2009-05-222034

Published: 2009

Includes: Supplemental data

Journal Articles

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Joyce James, PhD, Keith Pratz, Adam Stine, Julius L Apuy, PhD, Darren E Insko, PhD, Robert C Armstrong, Ph.D., Patrick P Zarrinkar, PhD, Donald Small, MD, PhD, Wendell Wierenga, PhD, Mark J. Levis, MD, PhD

Blood (2008) 112 (11): 2637.

https://doi.org/10.1182/blood.V112.11.2637.2637

Published: 2008

Journal Articles

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Patrick P Zarrinkar, PhD, Robert C Armstrong, Ph.D., Ruwanthi N Gunawardane, Ph.D., Joyce James, PhD, Mazen W Karaman, Ph.D., Shripad S Bhagwat, PhD

Blood (2008) 112 (11): 859.

https://doi.org/10.1182/blood.V112.11.859.859

Published: 2008

NARROW

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Detection of Phosphorylated and Total Flt3 and STAT5 in Whole Blood: Modulation by AC220 From Phase I and II Trials in AML

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.

AC220, a FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration.

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only